{"id":"https://openalex.org/W2074067653","doi":"https://doi.org/10.1200/jco.2011.38.2614","title":"Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to Bedside","display_name":"Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to Bedside","publication_year":2011,"publication_date":"2011-12-28","ids":{"openalex":"https://openalex.org/W2074067653","doi":"https://doi.org/10.1200/jco.2011.38.2614","mag":"2074067653","pmid":"https://pubmed.ncbi.nlm.nih.gov/22203760","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3295556"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.38.2614","doi":"https://doi.org/10.1200/jco.2011.38.2614","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.38.2614","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://europepmc.org/articles/PMC3295556","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043675371","display_name":"Vivek Subbiah","orcid":"https://orcid.org/0000-0002-6064-6837","observed_orcids":["https://orcid.org/0000-0002-6064-6837"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vivek Subbiah","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031648396","display_name":"John Mark Slopis","orcid":"https://orcid.org/0000-0002-1847-0583","observed_orcids":["https://orcid.org/0000-0002-1847-0583"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210102457","display_name":"Center for Neuro-Oncology","ror":"https://ror.org/00z2tp793","country_code":"US","type":"facility","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210102457","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Slopis","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX","Neuro-Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Neuro-Oncology","institution_ids":["https://openalex.org/I4210102457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David S. Hong","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020036393","display_name":"Leena Ketonen","orcid":"https://orcid.org/0000-0001-5263-9875","observed_orcids":["https://orcid.org/0000-0001-5263-9875"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leena M. Ketonen","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026967516","display_name":"Jackson D. Hamilton","orcid":"https://orcid.org/0000-0001-7335-8706","observed_orcids":["https://orcid.org/0000-0001-7335-8706"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jackson Hamilton","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010502061","display_name":"Ian E. McCutcheon","orcid":"https://orcid.org/0000-0002-1638-3400","observed_orcids":["https://orcid.org/0000-0002-1638-3400"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian E. McCutcheon","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX","Neurosurgery"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Neurosurgery","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.8372,"has_fulltext":false,"cited_by_count":48,"citation_normalized_percentile":{"value":0.89995984,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"30","issue":"5","first_page":"e64","last_page":"e68"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11173","display_name":"Neurofibromatosis and Schwannoma Cases","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11173","display_name":"Neurofibromatosis and Schwannoma Cases","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11251","display_name":"Meningioma and schwannoma management","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neurofibromatosis-type-2","display_name":"neurofibromatosis type 2","score":0.9990000128746033},{"id":"https://openalex.org/keywords/merlin","display_name":"Merlin","score":0.8140000104904175},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.8140000104904175},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.8109999895095825},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9940000176429749},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.7350000143051147},{"id":"https://openalex.org/keywords/pi3k-akt-signaling","display_name":"PI3K/Akt signaling","score":0.777999997138977},{"id":"https://openalex.org/keywords/mtor-signaling","display_name":"mTOR signaling","score":0.781000018119812},{"id":"https://openalex.org/keywords/raf-mek-erk-pathway","display_name":"Raf/MEK/ERK pathway","score":0.8740000128746033},{"id":"https://openalex.org/keywords/vestibular-schwannoma","display_name":"vestibular schwannoma","score":0.7210000157356262},{"id":"https://openalex.org/keywords/unresectable-tumors","display_name":"unresectable tumors","score":0.7419999837875366},{"id":"https://openalex.org/keywords/translational-research","display_name":"translational research","score":0.4740000069141388},{"id":"https://openalex.org/keywords/tumor-regression","display_name":"tumor regression","score":0.3240000009536743}],"concepts":[{"id":"https://openalex.org/C2778679214","wikidata":"https://www.wikidata.org/wiki/Q1935832","display_name":"Neurofibromatosis type 2","level":3,"score":0.8957676291465759},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8235636949539185},{"id":"https://openalex.org/C178628643","wikidata":"https://www.wikidata.org/wiki/Q410233","display_name":"Merlin (protein)","level":4,"score":0.7371479868888855},{"id":"https://openalex.org/C2778984943","wikidata":"https://www.wikidata.org/wiki/Q847605","display_name":"Neurofibromatosis","level":2,"score":0.5169572234153748},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4757673144340515},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.41879117488861084},{"id":"https://openalex.org/C2778264664","wikidata":"https://www.wikidata.org/wiki/Q422445","display_name":"Tumor suppressor gene","level":4,"score":0.4124254584312439},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.4033345878124237},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35636353492736816},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.318935751914978},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.277929425239563},{"id":"https://openalex.org/C555283112","wikidata":"https://www.wikidata.org/wiki/Q1637543","display_name":"Carcinogenesis","level":3,"score":0.1716657280921936},{"id":"https://openalex.org/C179185449","wikidata":"https://www.wikidata.org/wiki/Q219699","display_name":"Suppressor","level":3,"score":0.113709956407547}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077157","descriptor_name":"Sorafenib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077210","descriptor_name":"Sunitinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009536","descriptor_name":"Niacinamide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014635","descriptor_name":"Valproic Acid","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016518","descriptor_name":"Neurofibromatosis 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016518","descriptor_name":"Neurofibromatosis 2","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1200/jco.2011.38.2614","doi":"https://doi.org/10.1200/jco.2011.38.2614","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.38.2614","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2568459","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3295556","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3295556","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3295556","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Clin Oncol","raw_type":"Text"},{"id":"pmid:22203760","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22203760","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:2568459","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3295556","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8600000143051147,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1901027039","display_name":null,"funder_award_id":"CA 016672","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G8204861448","display_name":"Phase I Studies of Targeted Anti-Cancer Therapies","funder_award_id":"U01CA062461","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000878657","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA016672","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332521","display_name":"University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320337376","display_name":"NIH Clinical Center","ror":"https://ror.org/04vfsmv21"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":12,"referenced_works":["https://openalex.org/W1881950878","https://openalex.org/W1973106770","https://openalex.org/W2017423154","https://openalex.org/W2018958796","https://openalex.org/W2023011946","https://openalex.org/W2026383115","https://openalex.org/W2101219402","https://openalex.org/W2108073386","https://openalex.org/W2141007603","https://openalex.org/W2168778512","https://openalex.org/W2170249858","https://openalex.org/W4236250511"],"related_works":["https://openalex.org/W2127124297","https://openalex.org/W2585222863","https://openalex.org/W2589808799","https://openalex.org/W7161420649","https://openalex.org/W2604263340","https://openalex.org/W2147230566","https://openalex.org/W4384785182","https://openalex.org/W4377565052","https://openalex.org/W7165758760","https://openalex.org/W2059235828"],"abstract_inverted_index":{"Minimal":[0],"treatment":[1,131],"options":[2,117,184],"exist":[3],"for":[4,132,187,300,348,360],"advanced,":[5],"inoperable":[6],"neurofibromatosis":[7,37],"type":[8,38],"2":[9],"(NF2),":[10],"which":[11,40,74,126,211,335],"is":[12,31,56,127,228,266],"a":[13,20,43,203,338,344],"rare":[14],"tumor-prone":[15],"disorder.":[16],"NF2":[17,24,30,55,89,190,198,265,274,292],"results":[18,41],"from":[19,36,42,93,157],"mutation":[21,44],"in":[22,45,58,86,112,136,174,202,246,264,312,318],"the":[23,46,66,128,145,161,207,233,251,286,297,329],"tumor-suppressor":[25,48],"gene":[26,49],"on":[27,51],"chromosome":[28,52],"22q12.":[29],"genetically":[32],"and":[33,63,82,105,148,169,221,280,343,368],"phenotypically":[34],"distinguished":[35],"1,":[39],"NF1":[47],"located":[50],"17q11.1,2":[53],"Clinically,":[54],"inherited":[57],"an":[59,200],"autosomal":[60],"dominant":[61],"fashion":[62],"manifests":[64],"through":[65],"appearance":[67],"of":[68,124,130,144,151,210,224,232,253,256,288,340,346],"bilateral":[69],"acoustic":[70],"neuromas":[71],"(vestibular":[72],"schwannomas),":[73],"lead":[75,108],"to":[76,109,120,296,321,357],"progressive":[77],"hearing":[78],"loss.3":[79],"Vestibular":[80],"schwannomas":[81],"other":[83,94],"lesions":[84],"seen":[85],"patients":[87,122,154,188,196,272,290],"with":[88,189,191,197,273,291,365],"that":[90,230,236,240],"arise":[91],"progressively":[92],"sites,":[95],"such":[96],"as":[97],"meningiomas,":[98],"spinal":[99],"schwannomas,":[100],"astrocytomas,":[101],"ependymomas,":[102],"rarely":[103],"neurofibromas,":[104],"peripheral":[106],"neuropathies,":[107],"profound":[110],"morbidity":[111],"this":[113,152,349],"debilitating":[114],"disease.1,4":[115],"Few":[116],"are":[118,185],"available":[119,186],"these":[121,179,238],"outside":[123],"surgery,":[125],"mainstay":[129],"NF2-associated":[133],"lesions,":[134],"and,":[135],"some":[137],"instances,":[138],"radiation":[139],"therapy.1,2":[140],"Despite":[141],"our":[142],"understanding":[143],"underlying":[146],"genetics":[147],"molecular":[149],"pathophysiology":[150],"disorder,":[153],"become":[155],"debilitated":[156],"tumor-related":[158],"comorbidities.":[159],"Recently,":[160],"anti\u2013vascular":[162],"endothelial":[163],"growth":[164],"factor":[165],"(VEGF)":[166],"antibody":[167],"bevacizumab":[168],"erlotinib":[170],"exhibited":[171],"promising":[172],"activity":[173,245],"pilot":[175],"trials.5\u20138":[176],"Other":[177],"than":[178,314],"two":[180],"agents,":[181],"no":[182],"medical":[183],"surgically":[192],"unresectable":[193],"disease.":[194],"Because":[195],"harbor":[199],"aberration":[201],"single":[204],"gene,":[205],"merlin,":[206],"protein":[208],"product":[209],"impacts":[212],"multiple":[213],"signals,":[214],"including":[215],"PI3-kinase/Akt,":[216],"Raf/mitogen-activated":[217],"protein/extracellular":[218],"signal-regulated":[219],"kinase,":[220],"mammalian":[222],"target":[223,237],"rapamycin":[225],"(mTOR),":[226],"it":[227],"conceivable":[229],"one":[231,315],"many":[234],"agents":[235],"pathways":[239],"have":[241],"already":[242],"shown":[243],"antitumor":[244],"malignancies":[247],"will":[248],"also":[249,336],"cause":[250],"regression":[252],"NF2-related":[254],"tumors.9\u201311\r\n\r\nBecause":[255],"its":[257],"extreme":[258],"rarity,":[259],"conducting":[260],"large":[261],"clinical":[262],"trials":[263,279,325],"generally":[267],"unfeasible.9":[268],"Therefore,":[269],"we":[270],"enrolled":[271],"onto":[275],"various":[276],"rationally":[277],"targeted":[278],"sought":[281],"response":[282,361],"signals.":[283],"We":[284],"reviewed":[285],"records":[287],"consecutive":[289],"who":[293,309],"were":[294,310,326,353],"referred":[295],"Clinical":[298,305],"Center":[299],"Targeted":[301],"Therapy":[302],"(phase":[303],"I":[304],"Trials":[306],"Program":[307],"clinic)":[308],"treated":[311],"more":[313],"trial":[316],"starting":[317],"January":[319],"2007":[320],"December":[322],"2010.":[323],"All":[324],"approved":[327],"by":[328,362],"MD":[330],"Anderson":[331],"institutional":[332],"review":[333],"board,":[334],"granted":[337],"waiver":[339,345],"informed":[341],"consent":[342],"authorization":[347],"retrospective":[350],"study.":[351],"Patients":[352],"evaluated":[354],"every":[355],"6":[356],"8":[358],"weeks":[359],"using":[363],"RECIST":[364],"computed":[366],"tomography":[367],"magnetic":[369],"resonance":[370],"imaging.":[371]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2016-06-24T00:00:00"}